DNLI - Denali Therapeutics GAAP EPS of -$0.84 misses by $0.06
- Denali Therapeutics press release ( NASDAQ: DNLI ): Q3 GAAP EPS of -$0.84 misses by $0.06 .
- Collaboration Revenue of $3.56M (-32.7% Y/Y).
- Cash, cash equivalents, and marketable securities were approximately $1.11 billion as of September 30, 2022.
For further details see:
Denali Therapeutics GAAP EPS of -$0.84 misses by $0.06